Welcome to our dedicated page for Orthofix Med news (Ticker: OFIX), a resource for investors and traders seeking the latest updates and insights on Orthofix Med stock.
Orthofix Medical Inc. (NASDAQ: OFIX) is a leading medical device company providing orthopedic and spine solutions to healthcare providers worldwide. Founded in 1980 by orthopedic researcher Giovanni De Bastiani in Verona, Italy, the company has expanded to over 900 employees and operates in the U.S., Italy, Germany, France, the UK, Brazil, Australia, and Puerto Rico. Orthofix's products serve patients in more than 70 countries, focusing on enhancing patient quality of life through innovative medical solutions.
The company is structured into four strategic business units:
- BioStim: Offering bone growth stimulators using pulsed electromagnetic field technology.
- Biologics: Providing regenerative tissue products and biological solutions for bone and soft tissue repair.
- Extremity Fixation: Specializing in devices for fracture repair, deformity correction, and bone reconstruction.
- Spine Fixation: Delivering comprehensive solutions for spinal implants and bone healing therapies.
Orthofix is committed to clinical research and innovation, continuously introducing new products to meet the evolving needs of the medical community. The company maintains strong partnerships with esteemed institutions like the Texas Scottish Rite Hospital for Children and the Musculoskeletal Transplant Foundation, reflecting its dedication to advancing orthopedic and spine care.
The majority of Orthofix's sales come from its global spine segment, primarily in the United States. The company's products are distributed through sales representatives, distributors, and subsidiaries across North America, Europe, and other international markets. Orthofix's solutions cater to hospitals, physicians, healthcare providers, and patients, aiming to improve treatment outcomes and patient well-being.
Latest News: Stay updated with the latest developments, product launches, and financial reports from Orthofix Medical Inc. to keep track of the company's performance and strategic initiatives.
Orthofix Medical reported its Q4 and FY 2020 financial results, showing Q4 net sales of $117.6 million, a decline of 3.2% year-over-year. The company recorded a net loss of $9.4 million, or $(0.48) per share. Adjusted EPS was $0.44. For FY 2020, net sales reached $406.6 million with EPS of $0.13. The company highlighted operational resilience amidst COVID-19 disruptions and noted an expanded FDA clearance for the FITBONE® system. Guidance for 2021 anticipates net sales between $445 million and $460 million, reflecting a year-over-year increase.
Orthofix Medical Inc. (NASDAQ:OFIX) announced that its President and CEO, Jon Serbousek, and CFO, Doug Rice, will participate in a fireside chat at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Virtual Conference on February 19, 2021, at 9:30 a.m. ET. This virtual event will include one-on-one meetings before and after the chat. A live audio webcast will be available on Orthofix's website for those interested in following the discussion.
Orthofix, based in Lewisville, Texas, focuses on innovative medical device solutions for spine and extremities.
Orthofix Medical Inc. (NASDAQ:OFIX) has announced its plans to report financial results for the fourth quarter and full year 2020 on February 26, 2021, before market open. CEO Jon Serbousek and CFO Doug Rice will discuss the results during a conference call at 8:30 a.m. ET that day. Interested participants can join the call by dialing specific numbers or access a webcast through the company's investor relations website. Orthofix is focused on innovative medical device solutions, distributing products in over 70 countries.
Orthofix Medical Inc. (NASDAQ:OFIX) announced the full market launch of its FITBONE® intramedullary lengthening system in the U.S. and Europe for femur and tibia deformity corrections. The system, which is fully implantable, has been used in over 3,500 cases across 15 countries. It gained U.S. FDA 510(k) clearance and CE Mark approval in Europe. This expansion aims to improve treatment options for surgeons and patients. Orthofix offers a comprehensive portfolio of fixation solutions, enhancing its market presence in orthopedic care.
Orthofix Medical (NASDAQ:OFIX) published two-year data from its U.S. IDE study of the M6-C™ artificial cervical disc, demonstrating that the device is safe and effective for treating cervical disc degeneration. The study showed an overall success rate of 86.8% for M6-C patients compared to 79.3% for anterior cervical discectomy and fusion (ACDF) patients. At 24 months, M6-C patients reported significant reductions in pain and medication use, with a 91.2% improvement in neck pain. Orthofix aims to enhance patient outcomes with this innovative technology, emphasizing its commitment to quality-driven medical solutions.
Orthofix Medical Inc. (NASDAQ:OFIX) reported preliminary fourth quarter 2020 net sales of approximately $118 million, down 3% year-over-year. Full year net sales totaled about $407 million, a 12% decrease from 2019. Sequentially, Q4 sales rose 6% from Q3 2020, driven mainly by the Spinal Implants segment. Despite COVID-19 challenges, the company noted stable sales in Bone Growth Therapies and growth in Spinal Implants due to the M6-C™ artificial cervical disc. Cash reserves improved to approximately $96-97 million compared to $70 million in 2019.
Orthofix Medical announced participation in two investor conferences on January 14, 2021. President Jon Serbousek and CFO Doug Rice will present at the J.P. Morgan Healthcare Conference at 2:00pm ET and the ICR Westwicke Conference at 4:00pm ET. Both presentations will be live-streamed and accessible on the company's investor relations website. Orthofix, headquartered in Lewisville, Texas, focuses on innovative medical devices and biologics for spine and extremities, distributing products in over 70 countries.
Orthofix Medical Inc. (NASDAQ: OFIX) announced that President and CEO Jon Serbousek will participate in a fireside chat at the Stifel 2020 Virtual Healthcare Conference on November 16, 2020, at 10:40 a.m. ET. The event will be virtual, including one-on-one meetings surrounding the chat. A live audio webcast will be accessible on the company's website.
Orthofix is a global medical device and biologics company focused on spine and extremities, distributing products in over 70 countries and partnering with healthcare professionals to improve patient lives.
Orthofix Medical Inc. (NASDAQ: OFIX) has announced its plans to release financial results for Q3 2020 on November 5, 2020, before market open. CEO Jon Serbousek and CFO Doug Rice will host a conference call at 8:30 a.m. ET that same day to discuss the results. Interested parties can join the call by dialing the provided numbers, and a replay will be available for three weeks. Orthofix focuses on musculoskeletal products and therapies, distributing its offerings in over 70 countries.
FAQ
What is the current stock price of Orthofix Med (OFIX)?
What is the market cap of Orthofix Med (OFIX)?
What does Orthofix Medical Inc. specialize in?
Where is Orthofix Medical Inc. headquartered?
What are the main business units of Orthofix?
How does Orthofix distribute its products?
What partnerships does Orthofix have?
In how many countries are Orthofix products available?
What segment generates the majority of Orthofix's sales?
What are some key products offered by Orthofix?
How many employees does Orthofix have?
When was Orthofix Medical Inc. founded?
